Obesity Drugs: Worth a Weighty Investment

S&P sees huge potential for Big Pharma in the $70 billion global market for compounds to treat obesity and related disorders

The worldwide obesity epidemic threatens to place a heavy burden on government health-care budgets. Yet the burgeoning industry in drugs to treat excessive weight and obesity and the life-threatening diseases they cause could be worth its weight in gold to pharmaceutical companies.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.